Acylguanidine Beta Secretase 1 Inhibitors: A Combined Experimental and Free Energy Perturbation Study.

A series of acylguanidine beta secretase 1 (BACE1) inhibitors with modified scaffold and P3 pocket substituent was synthesized and studied with free energy perturbation (FEP) calculations. The resulting molecules showed potencies in enzymatic BACE1 inhibition assays up to 1 nM. The correlation between the predicted activity from the FEP calculations and the experimental activity was good for the P3 pocket substituents. The average mean unsigned error (MUE) between prediction and experiment was 0.68 ± 0.17 kcal/mol for the default 5 ns lambda window simulation time improving to 0.35 ± 0.13 kcal/mol for 40 ns. FEP calculations for the P2' pocket substituents on the same acylguanidine scaffold also showed good agreement with experiment and the results remained stable with repeated simulations and increased simulation time. It proved more difficult to use FEP calculations to study the scaffold modification from increasing 5 to 6 and 7 membered-rings. Although prediction and experiment were in agreement for short 2 ns simulations, as the simulation time increased the results diverged. This was improved by the use of a newly developed "Core Hopping FEP+" approach, which also showed improved stability in repeat calculations. The origins of these differences along with the value of repeat and longer simulation times are discussed. This work provides a further example of the use of FEP as a computational tool for molecular design.

[1]  A. Cavalli,et al.  Role of Molecular Dynamics and Related Methods in Drug Discovery. , 2016, Journal of medicinal chemistry.

[2]  William L Jorgensen,et al.  Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. , 2011, Journal of medicinal chemistry.

[3]  P. A. Bash,et al.  Free energy calculations by computer simulation. , 1987, Science.

[4]  Jakub Jończyk,et al.  Therapeutic strategies for Alzheimer’s disease in clinical trials , 2016, Pharmacological reports : PR.

[5]  Jennifer L. Knight,et al.  Modeling Local Structural Rearrangements Using FEP/REST: Application to Relative Binding Affinity Predictions of CDK2 Inhibitors. , 2013, Journal of chemical theory and computation.

[6]  X. Langlois,et al.  Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors. , 2015, ACS medicinal chemistry letters.

[7]  Ó. Delgado,et al.  1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads. , 2015, Journal of medicinal chemistry.

[8]  J. Malmström,et al.  Core refinement toward permeable β-secretase (BACE-1) inhibitors with low hERG activity. , 2013, Journal of medicinal chemistry.

[9]  X. Langlois,et al.  triazolo [ 4 , 3 ‐ a ] pyrazines as Selective , Brain Penetrant Phosphodiesterase 2 ( PDE 2 ) Inhibitors , 2015 .

[10]  Rajiv Chopra,et al.  Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors. , 2010, Journal of medicinal chemistry.

[11]  M. Karplus,et al.  Dynamics of folded proteins , 1977, Nature.

[12]  B. Roux,et al.  Computations of standard binding free energies with molecular dynamics simulations. , 2009, The journal of physical chemistry. B.

[13]  B. Berne,et al.  Replica exchange with solute tempering: a method for sampling biological systems in explicit water. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[15]  Jennifer L. Knight,et al.  Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. , 2015, Journal of the American Chemical Society.

[16]  J. A. McCammon,et al.  Dynamics and Design of Enzymes and Inhibitors. , 1986 .

[17]  Holger Gohlke,et al.  Binding Free Energy Calculations for Lead Optimization: Assessment of Their Accuracy in an Industrial Drug Design Context. , 2014, Journal of chemical theory and computation.

[18]  J. Essex,et al.  Hit identification and binding mode predictions by rigorous free energy simulations. , 2008, Journal of medicinal chemistry.

[19]  Woody Sherman,et al.  ConfGen: A Conformational Search Method for Efficient Generation of Bioactive Conformers , 2010, J. Chem. Inf. Model..

[20]  Thomas Fox,et al.  Accuracy Assessment and Automation of Free Energy Calculations for Drug Design , 2014, J. Chem. Inf. Model..

[21]  Shuai Liu,et al.  Lead optimization mapper: automating free energy calculations for lead optimization , 2013, Journal of Computer-Aided Molecular Design.

[22]  Sahil Patel,et al.  Apo and Inhibitor Complex Structures of BACE (β-secretase) , 2004 .

[23]  W. Guba,et al.  BACE1 inhibitors: a head group scan on a series of amides. , 2013, Bioorganic & medicinal chemistry letters.

[24]  David L. Mobley,et al.  Sensitivity in binding free energies due to protein reorganization , 2016 .

[25]  Peter V Coveney,et al.  On the calculation of equilibrium thermodynamic properties from molecular dynamics. , 2016, Physical chemistry chemical physics : PCCP.

[26]  Daniel Cappel,et al.  Accurate Binding Free Energy Predictions in Fragment Optimization , 2015, J. Chem. Inf. Model..

[27]  Matthew S. Johnson,et al.  Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors. , 2009, Journal of medicinal chemistry.

[28]  Samuel Genheden,et al.  A Large-Scale Test of Free-Energy Simulation Estimates of Protein-Ligand Binding Affinities , 2014, J. Chem. Inf. Model..

[29]  Daniel Oehlrich,et al.  The evolution of amidine-based brain penetrant BACE1 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[30]  J. Ellman,et al.  The tert-Butanesulfinyl Group: An Ideal Chiral Directing Group and Boc-Surrogate for the Asymmetric Synthesis and Applications of β-Amino Acids. , 1999 .

[31]  J. Spurlino,et al.  Rational design and synthesis of aminopiperazinones as β-secretase (BACE) inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[32]  Matthew S. Johnson,et al.  Di-substituted pyridinyl aminohydantoins as potent and highly selective human beta-secretase (BACE1) inhibitors. , 2010, Bioorganic & medicinal chemistry.

[33]  Laura Pérez-Benito,et al.  Application of Free Energy Perturbation for the Design of BACE1 Inhibitors , 2016, J. Chem. Inf. Model..

[34]  Jacob D. Durrant,et al.  Molecular dynamics simulations and drug discovery , 2011, BMC Biology.

[35]  Peter A. Kollman,et al.  Free energy perturbation simulations of the inhibition of thermolysin: prediction of the free energy of binding of a new inhibitor , 1989 .

[36]  Atli Thorarensen,et al.  Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free‐Energy Perturbation (FEP) , 2016, ChemMedChem.

[37]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[38]  Edward D Harder,et al.  How To Deal with Multiple Binding Poses in Alchemical Relative Protein–Ligand Binding Free Energy Calculations , 2015, Journal of chemical theory and computation.

[39]  Lingle Wang,et al.  Correction to “Replica Exchange with Solute Scaling: A More Efficient Version of Replica Exchange with Solute Tempering (REST2)” , 2011 .

[40]  J. Ellman,et al.  The tert-Butanesulfinyl Group: An Ideal Chiral Directing Group and Boc-Surrogate for the Asymmetric Synthesis and Applications of beta-Amino Acids. , 1999, The Journal of organic chemistry.

[41]  Robert Abel,et al.  Accurate Modeling of Scaffold Hopping Transformations in Drug Discovery. , 2017, Journal of chemical theory and computation.

[42]  W. L. Jorgensen,et al.  Monte Carlo simulation of differences in free energies of hydration , 1985 .

[43]  W. L. Jorgensen.  Efficient Drug Lead Discovery and Optimization , 2009 .

[44]  D. Banner,et al.  Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones. , 2013, Acta crystallographica. Section D, Biological crystallography.

[45]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[46]  Jürgen Bajorath,et al.  Advances in Computational Medicinal Chemistry: A Reflection on the Evolution of the Field and Perspective Going Forward. , 2016, Journal of medicinal chemistry.

[47]  Jennifer L. Knight,et al.  OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. , 2016, Journal of chemical theory and computation.